Cargando…

Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors

BACKGROUND: Lung neuroendocrine tumors account for approximately 15% of all lung cancer cases. LNET are subdivided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung cancer (SCLC). The Ki-67 index has been used for decades to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Orozco-Morales, Mario, Avilés-Salas, Alejandro, Hernández-Pedro, Norma, Catalán, Rodrigo, Cruz-Rico, Graciela, Colín-González, Ana Laura, Dosal-Mancilla, Elsa, Barrios-Bernal, Pedro, Arrieta, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214491/
https://www.ncbi.nlm.nih.gov/pubmed/34195295
http://dx.doi.org/10.1155/2021/6632249
_version_ 1783710073790398464
author Orozco-Morales, Mario
Avilés-Salas, Alejandro
Hernández-Pedro, Norma
Catalán, Rodrigo
Cruz-Rico, Graciela
Colín-González, Ana Laura
Dosal-Mancilla, Elsa
Barrios-Bernal, Pedro
Arrieta, Oscar
author_facet Orozco-Morales, Mario
Avilés-Salas, Alejandro
Hernández-Pedro, Norma
Catalán, Rodrigo
Cruz-Rico, Graciela
Colín-González, Ana Laura
Dosal-Mancilla, Elsa
Barrios-Bernal, Pedro
Arrieta, Oscar
author_sort Orozco-Morales, Mario
collection PubMed
description BACKGROUND: Lung neuroendocrine tumors account for approximately 15% of all lung cancer cases. LNET are subdivided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung cancer (SCLC). The Ki-67 index has been used for decades to evaluate mitotic counts however, the role of Ki-67 as a biomarker for assessing prognosis and guiding therapy in metastatic LNET still lacks feasible clinical validation. Recent clinical trials have indicated that inhibition of CD47 with anti-CD47 antibodies exerts a promising antitumor effect against several human malignancies, including NSCLC, melanoma, and hematologic malignancies. However, the clinical relevance of CD47 expression in LNET has remained unclear. METHODS: We performed a retrospective study in which we analyzed tumor biopsies from 51 patients with a confirmed diagnosis of LNET that received treatment at our hospital. Then, we analyzed if there was any correlation between CD47 expression with any clinical or pathological characteristic. We also analyzed the prognostic significance of CD47, assessed as progression-free survival and overall survival. RESULTS: A total of 51 patients with LNET were enrolled in our study. The mean age at diagnosis was 57.6 (±11.6) years; 30 patients were women (59%). 27.5% of patients were positive for CD47 expression, and 72.5% of patients showed a CD47 expression of less than 1% and were considered as negatives. In patients with high-grade tumors (this time defined as Ki‐67 > 40%), the positive expression of CD47 was strongly associated with an increased PFS. Albeit, these differences did not reach statistical significance when analyzing OS. CONCLUSION: Contrary to what happens in a wide range of hematologic and solid tumors, a higher expression of CD47 in patients with LNET is associated with a better progression-free survival, especially in patients with a Ki‐67 ≥ 40%. This “paradox” remains to be confirmed and explained by larger studies.
format Online
Article
Text
id pubmed-8214491
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-82144912021-06-29 Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors Orozco-Morales, Mario Avilés-Salas, Alejandro Hernández-Pedro, Norma Catalán, Rodrigo Cruz-Rico, Graciela Colín-González, Ana Laura Dosal-Mancilla, Elsa Barrios-Bernal, Pedro Arrieta, Oscar J Immunol Res Research Article BACKGROUND: Lung neuroendocrine tumors account for approximately 15% of all lung cancer cases. LNET are subdivided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung cancer (SCLC). The Ki-67 index has been used for decades to evaluate mitotic counts however, the role of Ki-67 as a biomarker for assessing prognosis and guiding therapy in metastatic LNET still lacks feasible clinical validation. Recent clinical trials have indicated that inhibition of CD47 with anti-CD47 antibodies exerts a promising antitumor effect against several human malignancies, including NSCLC, melanoma, and hematologic malignancies. However, the clinical relevance of CD47 expression in LNET has remained unclear. METHODS: We performed a retrospective study in which we analyzed tumor biopsies from 51 patients with a confirmed diagnosis of LNET that received treatment at our hospital. Then, we analyzed if there was any correlation between CD47 expression with any clinical or pathological characteristic. We also analyzed the prognostic significance of CD47, assessed as progression-free survival and overall survival. RESULTS: A total of 51 patients with LNET were enrolled in our study. The mean age at diagnosis was 57.6 (±11.6) years; 30 patients were women (59%). 27.5% of patients were positive for CD47 expression, and 72.5% of patients showed a CD47 expression of less than 1% and were considered as negatives. In patients with high-grade tumors (this time defined as Ki‐67 > 40%), the positive expression of CD47 was strongly associated with an increased PFS. Albeit, these differences did not reach statistical significance when analyzing OS. CONCLUSION: Contrary to what happens in a wide range of hematologic and solid tumors, a higher expression of CD47 in patients with LNET is associated with a better progression-free survival, especially in patients with a Ki‐67 ≥ 40%. This “paradox” remains to be confirmed and explained by larger studies. Hindawi 2021-06-11 /pmc/articles/PMC8214491/ /pubmed/34195295 http://dx.doi.org/10.1155/2021/6632249 Text en Copyright © 2021 Mario Orozco-Morales et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Orozco-Morales, Mario
Avilés-Salas, Alejandro
Hernández-Pedro, Norma
Catalán, Rodrigo
Cruz-Rico, Graciela
Colín-González, Ana Laura
Dosal-Mancilla, Elsa
Barrios-Bernal, Pedro
Arrieta, Oscar
Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
title Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
title_full Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
title_fullStr Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
title_full_unstemmed Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
title_short Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
title_sort clinicopathological and prognostic significance of cd47 expression in lung neuroendocrine tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214491/
https://www.ncbi.nlm.nih.gov/pubmed/34195295
http://dx.doi.org/10.1155/2021/6632249
work_keys_str_mv AT orozcomoralesmario clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors
AT avilessalasalejandro clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors
AT hernandezpedronorma clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors
AT catalanrodrigo clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors
AT cruzricograciela clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors
AT colingonzalezanalaura clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors
AT dosalmancillaelsa clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors
AT barriosbernalpedro clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors
AT arrietaoscar clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors